A
Andrew Jeremijenko
Researcher at Hamad Medical Corporation
Publications - 98
Citations - 4478
Andrew Jeremijenko is an academic researcher from Hamad Medical Corporation. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 19, co-authored 54 publications receiving 1173 citations. Previous affiliations of Andrew Jeremijenko include World Health Organization & University of Western Australia.
Papers
More filters
Posted ContentDOI
Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
Hiam Chemaitelly,Hiam Chemaitelly,Patrick Tang,Mohammad Rubayet Hasan,Sawsan AlMukdad,Sawsan AlMukdad,Hadi M. Yassine,Hadi M. Yassine,Fatiha M. Benslimane,Fatiha M. Benslimane,Hebah A. Al Khatib,Hebah A. Al Khatib,Peter Coyle,Peter Coyle,Peter Coyle,Houssein H. Ayoub,Zaina Al Kanaani,Einas Al Kuwari,Andrew Jeremijenko,Anvar Hassan Kaleeckal,Ali Nizar Latif,Riyazuddin Mohammad Shaik,Hanan F. Abdul Rahim,Gheyath K. Nasrallah,Gheyath K. Nasrallah,Mohamed Ghaith Al Kuwari,Hamad Eid Al Romaihi,Adeel A. Butt,Adeel A. Butt,Mohamed H. Al-Thani,Abdullatif Al Khal,Roberto Bertollini,Laith J. Abu-Raddad +32 more
TL;DR: In this article, the authors investigated the persistence of BNT162b2 (Pfizer-BioNTech) vaccine effectiveness against infection and disease in Qatar, where the Beta and Delta variants have dominated incidence and PCR testing is done at a mass scale.
Journal ArticleDOI
Three Indonesian clusters of H5N1 virus infection in 2005.
I. Nyoman Kandun,Hariadi Wibisono,Endang R. Sedyaningsih,Yusharmen,Widarso Hadisoedarsuno,Wilfried H. Purba,Hari Santoso,Chita Septiawati,Erna Tresnaningsih,Bambang Heriyanto,Djoko Yuwono,Syahrial Harun,Santoso Soeroso,Sardikin Giriputra,Patrick J. Blair,Andrew Jeremijenko,Herman Kosasih,Shannon D. Putnam,Gina Samaan,Marlinggom Silitonga,Kwok-Hung Chan,Leo L.M. Poon,Wilina Lim,Alexander Klimov,Stephen Lindstrom,Yi Guan,Ruben O. Donis,Jacqueline M. Katz,Nancy J. Cox,Malik Peiris,Timothy M. Uyeki +30 more
TL;DR: Investigation of three clusters of Indonesian cases with at least two ill persons hospitalized with laboratory evidence of H5N1 virus infection from June through October 2005 found that clusters of human infection with clade 2 H5n1 viruses included mild, severe, and fatal cases among family members.
Journal ArticleDOI
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
Patrick Tang,Mohammad Rubayet Hasan,Hiam Chemaitelly,Hiam Chemaitelly,Hadi M. Yassine,Hadi M. Yassine,Fatiha M. Benslimane,Fatiha M. Benslimane,Hebah A. Al Khatib,Hebah A. Al Khatib,Sawsan AlMukdad,Sawsan AlMukdad,Peter Coyle,Peter Coyle,Peter Coyle,Houssein H. Ayoub,Zaina Al Kanaani,Einas Al Kuwari,Andrew Jeremijenko,Anvar Hassan Kaleeckal,Ali Nizar Latif,Riyazuddin Mohammad Shaik,Hanan F. Abdul Rahim,Gheyath K. Nasrallah,Gheyath K. Nasrallah,Mohamed Ghaith Al Kuwari,Hamad Eid Al Romaihi,Adeel A. Butt,Adeel A. Butt,Mohamed H. Al-Thani,Abdullatif Al Khal,Roberto Bertollini,Laith J. Abu-Raddad +32 more
TL;DR: In this article, the authors conducted a matched test-negative case-control study to assess the real-world effectiveness of COVID-19 messenger RNA vaccines against infection with Delta in Qatar's population.
Journal ArticleDOI
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.
Hiam Chemaitelly,Hiam Chemaitelly,Hadi M. Yassine,Hadi M. Yassine,Fatiha M. Benslimane,Fatiha M. Benslimane,Hebah A. Al Khatib,Hebah A. Al Khatib,Patrick Tang,Mohammad Rubayet Hasan,Joel A. Malek,Peter Coyle,Peter Coyle,Peter Coyle,Houssein H. Ayoub,Zaina Al Kanaani,Einas Al Kuwari,Andrew Jeremijenko,Anvar Hassan Kaleeckal,Ali Nizar Latif,Riyazuddin Mohammad Shaik,Hanan F. Abdul Rahim,Gheyath K. Nasrallah,Gheyath K. Nasrallah,Mohamed Ghaith Al Kuwari,Hamad Eid Al Romaihi,Mohamed H. Al-Thani,Abdullatif Al Khal,Adeel A. Butt,Adeel A. Butt,Roberto Bertollini,Laith J. Abu-Raddad,Laith J. Abu-Raddad +32 more
TL;DR: The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with ‘wild-type’ variants in a randomized clinical trial.
letters-and-commentsDOI
Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
Heba Altarawneh,Hiam Chemaitelly,Mohammad Rubayet Hasan,Houssein H. Ayoub,S. Qassim,Sawsan AlMukdad,Peter Coyle,Hadi M. Yassine,Hebah A. Al-Khatib,Fatiha M. Benslimane,Zaina Al-Kanaani,Einas Alkuwari,Andrew Jeremijenko,Anvar Hassan Kaleeckal,Ali Nizar Latif,Riyazuddin Mohammad Shaik,Hanan F. Abdul-Rahim,Gheyath K. Nasrallah,Mohamed Ghaith Al-Kuwari,Adeel A. Butt,Hamad Al-Romaihi,Mohamed H. Al-Thani,Abdullatif Al-Khal,Roberto Bertollini,Patrick Tang,Laith J. Abu-Raddad +25 more
TL;DR: It was showed that past infection effectively prevented reinfection with SARS-CoV-2 alpha, beta, and delta variants, confirming earlier estimates and seems to protect against hospitalization or mortality from reinfections, independent of variant.